Lumetry Diagnostics: Raiffeisenbank invests in Graz-based MedTech company
DE · Lumetry Diagnostics: Raiffeisenbank beteiligt sich an Grazer MedTech
Raiffeisenlandesbank Niederösterreich-Wien is taking a 10 percent stake in Lumetry Diagnostics as lead investor; the investment amount was not disclosed. The capital will help the Graz-based MedTech company launch the first CE-marked product version of its breath-analysis device for COPD patients in Europe. The device combines spirometry and capnography; AI-powered algorithms for a follow-up model are undergoing clinical trials.
Vezetői összefoglaló (AI)
- Raiffeisenlandesbank Niederösterreich-Wien is acquiring a 10 percent stake in Lumetry Diagnostics as lead investor; the investment amount was not disclosed.
- With this capital, the Graz-based MedTech company will launch the first CE-marked version of a breath analyzer for COPD patients in Europe.
- The device combines spirometry to measure lung volume and capnography to measure exhaled carbon dioxide; results are processed digitally.
- Co-CEO Christian Neubauer says the company aims to estimate carbon dioxide levels from exhaled air in the future and support early COPD detection.
- A follow-up model is in development; AI-powered algorithms for early COPD detection and blood CO₂ monitoring are undergoing clinical trials.
brutkastenEredeti olvasása ↗